Oxford, UK - 11 September 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today its interim financial results for the six months ended 30 June 2007. Year to date highlights:

Operational highlights:

TroVax^® (multiple cancers)

· Global development and commercialisation deal with sanofi-aventis

· Successful first DSMB review of Phase III TRIST study in renal cancer

· First milestone under sanofi-aventis agreement achieved

· Encouraging further Phase II results in renal cancer

· Sanofi-aventis to start Phase III trial in metastatic colorectal cancer

· QUASAR to start Phase III trial in early-stage colorectal cancer

ProSavin^® (Parkinson’s disease)

· Regulatory submission for start of Phase I/II trial in Parkinson’s disease

Other

· Acquisition of Oxxon Therapeutics for £16 million in shares

· Initiated new anti-cancer development programme

· Licensing agreement for LentiVector^® technology with major US biotechnology company

Financial highlights:

· Received initial payment of £19.7 million from sanofi-aventis

· Revenue recognised of £2.0 million (H1 2006: £0.2 million)

· Research and development costs of £10.8 million (H1 2006: £9.5 million)

· Loss after tax of £9.3 million (H1 2006: £8.7 million)

· Net cash generated¹ of £10.4 million (H1 2006: cash burn¹ £5.4 million)

· Gross cash and cash equivalents acquired with Oxxon Therapeutics of £3.8 million

· Net cash² at 30 June of £42.5 million (30 June 2006: £38.7 million)

1. Net cash generated/used in operating activities plus sales and purchases of non-current assets

2. Cash, cash equivalents and current financial assets

Commenting on the interim results, Oxford BioMedica’s Chief Executive, Professor Alan Kingsman, said: “We have made excellent progress in the first half of the year. Our collaboration with sanofi-aventis on TroVax is a significant event for the Company. It validates our development strategy for TroVax and the product’s potential commercial value. The payments from the collaboration have also put the Company in a strong financial position. Patient recruitment into the Phase III TRIST trial of TroVax in renal cancer continues to be rapid, and sanofi-aventis is now planning to start a Phase III trial in colorectal cancer. Following the completion of our landmark deal with sanofi-aventis, we conducted a strategic review of our pipeline to prioritise programmes for accelerated development in order to maximise shareholder value. Arising from this review is the key development priority of starting the first clinical trial of ProSavin in Parkinson’s disease, and we are on track with the regulatory process for this study. We look forward to pursuing our development and commercial goals with confidence. The Company has never been stronger than it is today.”

To view Chairman’s and chief executive’s report, click here

Analyst meeting:

An analyst briefing will be held at 10:00 am today at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.

Web cast:

Simultaneously to the analyst briefing at 10.00 am, there will be a live audio web cast of the results presentation. To connect to the web cast facility, please go to the Company’s website: http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (09:50 am) before the start of the briefing. This will also be available for replay shortly after the presentation.

-Ends-

For further information, please contact:

Oxford BioMedica plc:

Professor Alan Kingsman, Chief Executive

Tel: +44 (0)1865 783 000

City/Financial Enquiries:

Lisa Baderoon/ Mark Court/ Mary-Jane Johnson

Buchanan Communications

Tel: +44 (0)20 7466 5000

Scientific/Trade Press Enquiries:

Gemma Price/ Holly Griffiths/ Katja Stout

Northbank Communications

Tel: +44 (0)20 7268 3002

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of novel cancer immunotherapies and gene-based medicines. The Company was established in 1995 as a spin-out from Oxford University, and is listed on the London Stock Exchange.

The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica has in-house clinical, regulatory and manufacturing know-how. The lead product candidate is TroVax^®, an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialisation. A Phase III trial of TroVax in renal cancer is ongoing and Phase III trials in colorectal cancer are planned. Oxford BioMedica has two other oncology therapies in clinical development and expects to start a Phase I/II trial of its novel gene therapy for Parkinson’s disease, ProSavin^®, in 2007.

The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 80 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Corporate partners include sanofi-aventis for TroVax and Wyeth for a novel targeted antibody therapy. The Company also has collaborations with Sigma-Aldrich, MolMed and Virxsys and has licensed technology to multiple partners, including Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer.

Further information is available at www.oxfordbiomedica.co.uk